Liver Cancer Therapeutics Market Overview
Liver cancer signifies the fifth most generally arising cancer and the third foremost reason for deaths associated with cancer in the world. Hence, the liver cancer diagnosis and medication market is projected to become an active ground for competition in the coming few years. Several new-targeted therapies are predicted to arrive in the market in near future.
Directed cancer therapies practice medication to avoid the growth of cancer cells by intruding certain molecules, known as molecular targets, thus preventing the movement and growth of cancer cells. The treatment procedures mainly focus on the cellular and molecular variations, affecting precisely to cancer cells.
Major drivers for liver cancer therapeutics market are increasing aging population, more unmet requirements for the treatment of liver cancer, drug inventions with respect to the cancer, increasing government initiatives, rising occurrences of cancer and mounting health care expenditure. However, factors such as stringent regulatory processes, high capital investments, and low success rate in clinic trials for drugs and low approachability in remote areas are hindering the growth of liver cancer therapeutics market.
Liver Cancer Therapeutics Market Forecast Report (2018-2023)
Global Liver Cancer Therapeutics Market was worth $680.84 million in 2018 and estimated to be growing at a CAGR of 9.1%, to reach $1052.37 million by 2023.
Browse Report Brief and TOC @ https://www.marketdataforecast.com/market-reports/liver-cancer-therapeutics-market-836/
Liver Cancer Therapeutics Market Segmentation
The global liver cancer therapeutics market is segmented on the basis of type into primary, secondary and benign liver growths. On the basis of therapeutics, the market is bifurcated into hepatocellular carcinoma, Cholangio carcinoma, Hepatoblastoma and targeted therapy. By end-use the market is divided amongst pediatrics and adults. Hepatocellular Carcinoma is the largest segment for therapeutics type due to the high prevalence of this type of liver cancer among people.
Based on geography the market is analysed under various regions namely, North America, Latin America, Europe, Asia-Pacific and Middle-East & Africa. North America is the largest market for liver cancer therapeutics followed by Europe and Asia. Also, Asia-Pacific signifies the fastest growing region for liver cancer therapeutics market, owing to increasing aged populations. Increasing number of liver cancer cases in the Asian countries is further fuelling this regions market.
The major companies dominating this market for its products and services are
- Alnylam Pharmaceuticals Inc.,
- ImClone Systems Inc.,
- Onyx Pharmaceuticals Inc.,
- F. Hoffmann-La Roche Ltd.,
- Pfizer Inc.,
- ArQule Inc.,
- Jennerex Biotherapeutics Inc.,
- Celsion Corp.,
- Bayer Schering Pharma AG,
- 4SC AG,
- Bristol-Myers Squibb Company.
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.
For more information:
Sales Manager at Market Data Forecast